Short Interest in ChromaDex Co. (NASDAQ:CDXC) Grows By 6.7%

ChromaDex Co. (NASDAQ:CDXC - Get Free Report) was the target of a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 2,070,000 shares, an increase of 6.7% from the December 15th total of 1,940,000 shares. Based on an average trading volume of 1,270,000 shares, the days-to-cover ratio is currently 1.6 days. Approximately 4.3% of the shares of the stock are sold short.

Insider Buying and Selling at ChromaDex

In other ChromaDex news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $6.19, for a total transaction of $230,026.59. Following the completion of the sale, the director now directly owns 244,179 shares of the company's stock, valued at $1,511,468.01. This trade represents a 13.21 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 9.64% of the company's stock.

Institutional Investors Weigh In On ChromaDex

Several institutional investors have recently modified their holdings of CDXC. SG Americas Securities LLC raised its holdings in ChromaDex by 42.5% during the 4th quarter. SG Americas Securities LLC now owns 23,857 shares of the company's stock valued at $127,000 after buying an additional 7,117 shares during the period. USA Financial Formulas bought a new position in ChromaDex during the fourth quarter valued at $25,000. JPMorgan Chase & Co. raised its stake in shares of ChromaDex by 11.1% in the third quarter. JPMorgan Chase & Co. now owns 331,916 shares of the company's stock valued at $1,211,000 after acquiring an additional 33,150 shares during the period. Franklin Resources Inc. bought a new stake in shares of ChromaDex in the 3rd quarter worth about $68,000. Finally, Barclays PLC boosted its stake in shares of ChromaDex by 322.1% during the 3rd quarter. Barclays PLC now owns 70,072 shares of the company's stock worth $256,000 after purchasing an additional 53,472 shares during the period. 15.41% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on CDXC shares. HC Wainwright upped their target price on shares of ChromaDex from $6.00 to $8.00 and gave the stock a "buy" rating in a research report on Monday, November 4th. Roth Mkm raised their price objective on ChromaDex from $6.00 to $8.00 and gave the company a "buy" rating in a research report on Wednesday, November 6th. Finally, StockNews.com cut ChromaDex from a "strong-buy" rating to a "buy" rating in a report on Wednesday.

ChromaDex Trading Up 5.1 %

CDXC traded up $0.29 during trading hours on Friday, hitting $5.94. The company's stock had a trading volume of 364,834 shares, compared to its average volume of 436,868. The stock has a market cap of $453.70 million, a price-to-earnings ratio of 594.59 and a beta of 2.21. The business's 50-day moving average price is $6.34 and its 200-day moving average price is $4.45. ChromaDex has a 12 month low of $1.36 and a 12 month high of $7.97.

ChromaDex (NASDAQ:CDXC - Get Free Report) last announced its earnings results on Thursday, October 31st. The company reported $0.02 earnings per share (EPS) for the quarter. The firm had revenue of $25.58 million for the quarter, compared to analysts' expectations of $23.70 million. ChromaDex had a net margin of 1.62% and a return on equity of 4.85%. During the same period in the prior year, the company earned ($0.01) EPS. On average, analysts forecast that ChromaDex will post 0.04 earnings per share for the current year.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.